These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Bone marrow transplantation from genetically HLA-nonidentical donors in children with fatal inherited disorders excluding severe combined immunodeficiencies: use of two monoclonal antibodies to prevent graft rejection. Jabado N, Le Deist F, Cant A, De Graeff-Meeders ER, Fasth A, Morgan G, Vellodi A, Hale G, Bujan W, Thomas C, Cavazzana-Calvo M, Wijdenes J, Fischer A. Pediatrics; 1996 Sep; 98(3 Pt 1):420-8. PubMed ID: 8784367 [Abstract] [Full Text] [Related]
17. [Cellular sorting methods in autologous (elimination of residual malignant cells) or allogeneic (T lymphocyte elimination) bone marrow grafts. Clinical pilot studies]. Hervé P, Flesch M. Nouv Rev Fr Hematol (1978); 1986 Sep; 28(2):97-105. PubMed ID: 2942838 [Abstract] [Full Text] [Related]
18. A new approach to the prevention of graft-versus-host disease using XomaZyme-H65 following histo-incompatible partially T-depleted marrow grafts. Henslee PJ, Byers VS, Jennings CD, Marciniak E, Thompson JS, Macdonald JS, Romond EH, Messino MJ, Scannon PJ. Transplant Proc; 1989 Feb; 21(1 Pt 3):3004-7. PubMed ID: 2650413 [No Abstract] [Full Text] [Related]
19. Donor antigen-presenting cells regulate T-cell expansion and antitumor activity after allogeneic bone marrow transplantation. Li JM, Waller EK. Biol Blood Marrow Transplant; 2004 Aug; 10(8):540-51. PubMed ID: 15282532 [Abstract] [Full Text] [Related]
20. Effective graft-versus-leukemia effects independent of graft-versus-host disease after T cell-depleted allogeneic bone marrow transplantation in a murine model of B cell leukemia/lymphoma. Role of cell therapy and recombinant IL-2. Weiss L, Lubin I, Factorowich I, Lapidot Z, Reich S, Reisner Y, Slavin S. J Immunol; 1994 Sep 15; 153(6):2562-7. PubMed ID: 8077666 [Abstract] [Full Text] [Related] Page: [Next] [New Search]